<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03614858</url>
  </required_header>
  <id_info>
    <org_study_id>UnicarTherapy201807</org_study_id>
    <nct_id>NCT03614858</nct_id>
  </id_info>
  <brief_title>CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.</brief_title>
  <official_title>Pilot Study of the Efficacy and Safety of Cluster of Differentiation Antigen 19 (CD19) /Cluster of Differentiation Antigen 22 (CD22) CART in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, open-label ,phase 1/2 study to evaluate the safety and efficacy of
      targeted CD19/CD22 chimeric antigen receptor engineered T cell immunotherapy (CART) in the
      treatment of CD19/CD22 positive Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients will receive infusion of CART cells targeting CD19 and CD22 to confirm the
      safety and efficacy of CD19/CD22 CART Cells in Relapsed or Refractory B-Cell Acute
      Lymphoblastic Leukemia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse events are evaluated with CTCAE V4.03</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Leukemia, B-cell</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Cohort 1 Intervention: Biological: CART-19/22 This cohort will determine the safety and efficacy of targeted CD19/CD22 chimeric Antigen Receptor Engineered T Cell Immunotherapy (CART) in the Treatment of CD19/CD22 Positive Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CART-19/22</intervention_name>
    <description>Split intravenous infusion of CART-19/22 cells of (Dose escalating infusion of 1 - 20 x10^6 CART-19/22 cells/kg).</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients with CD19+/CD22+ relapsed/refractory B-cell acute
             lymphoblastic leukemia who have a dismal prognosis (estimated survival from several
             months to &lt;2 year). The study will enroll 20 evaluable patients as follows:

          -  Age 6-65 years.

          -  Left ventricular ejection fractions≥ 0.5 by echocardiography.

          -  Creatinine &lt; 1.6 mg/dL.

          -  Aspartate aminotransferase/aspartate aminotransferase &lt; 3x upper limit of normal.

          -  Bilirubin &lt;2.0 mg/dL.

          -  Karnofsky performance status ≥ 60

          -  Expected survival time ≥ 3 months (according to investigator's judgement)

        Exclusion Criteria:

          -  Pregnant or lactating women.

          -  Uncontrolled active infection.

          -  Active hepatitis B or hepatitis C infection.

          -  Class III/IV cardiovascular disability according to the New York Heart Association
             Classification.

          -  HIV infection.

          -  Patients with history of seizure

          -  Active central nervous system leukemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaowen Tang, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaowen Tang, Ph.D.</last_name>
    <phone>(0086)51267781856</phone>
    <email>tangxiaowen@suda.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lei Yu, Ph.D.</last_name>
    <phone>8613818629089</phone>
    <email>ylyh188@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaowen Tang, Ph.D</last_name>
      <phone>(0086)51267781856</phone>
      <email>tangxiaowen@suda.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>July 28, 2018</study_first_submitted>
  <study_first_submitted_qc>July 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>July 12, 2019</last_update_submitted>
  <last_update_submitted_qc>July 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD19</keyword>
  <keyword>CD22</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

